Drug pricing and the impact of rebates continues to be a fiercely debated topic in the pharmaceutical industry across legislators, public interest groups and industry insiders. (Photo: Shutterstock)
The White House has reversed its ruling from earlier this year that would have amended the safe harbor regulations eliminating traditional rebates and requiring discounts be moved to the point of sale. The ruling was designed to decrease the overall cost of drugs and lower the out-of-pocket cost burden for Medicare and Medicaid recipients with the largest impact being to the Medicare population and health plans.
While the proposed ruling was well-intentioned, most industry associations and organizations predicted that while it would decrease the member impact at the point of sale, the overall impact would likely produce higher premiums and increase the cost of the program to the federal government. Some estimated federal costs could expand by $177 billion over the next ten years.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.